Insider · CIK 0001778623

Veness Adam M

Reports to the SEC for 3 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001778623

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-13	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+15K sh	$18.17	+$273K	15,000
2026-08-13	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−15K sh	—	—	73,240
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+16.2K sh	$17.88	+$289K	16,167
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/S Sale	SVP, General Counsel and Sec.	SSale	−16.2K sh	$110.38	−$1.78M	0
2026-08-10	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−16.2K sh	—	—	60,000
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+3,833 sh	$17.88	+$68.5K	3,833
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	SVP, General Counsel and Sec.	SSale	−3,217 sh	$110.61	−$356K	616
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/S Sale	SVP, General Counsel and Sec.	SSale	−616 sh	$111.18	−$68.5K	0
2026-08-07	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−3,833 sh	—	—	76,167
2026-06-17	DNTHDianthus Therapeutics, Inc. /DE/M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+30K sh	$17.88	+$536K	30,000
2026-06-17	DNTHDianthus Therapeutics, Inc. /DE/S Sale	SVP, General Counsel and Sec.	SSale	−16.8K sh	$80.34	−$1.35M	13,229
2026-06-17	DNTHDianthus Therapeutics, Inc. /DE/S Sale	SVP, General Counsel and Sec.	SSale	−13.2K sh	$81.38	−$1.08M	0
2026-06-17	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)M Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−30K sh	—	—	80,000
2026-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	SVP, General Counsel and Sec.	AAward	+100K sh	—	—	100,000
2025-02-03	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	SVP, General Counsel and Sec.	AAward	+100K sh	—	—	100,000
2024-05-23	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	SVP, General Counsel and Sec.	AAward	+75K sh	—	—	75,000
2024-01-24	DNTHDianthus Therapeutics, Inc. /DE/ · Stock Option (Right to Buy)A Award	SVP, General Counsel and Sec.	AAward	+110K sh	—	—	110,000
2023-02-03	Cyteir Therapeutics, Inc.Stock Option (Right to Buy)A Award	General Counsel	AAward	+96.1K sh	—	—	96,100
2022-05-02	Cyteir Therapeutics, Inc.Stock Option (Right to buy)A Award	General Counsel	AAward	+177K sh	—	—	177,000
2021-11-19	ACCELERON PHARMA INCU Disposition from Tender	SVP, General Counsel and Sec.	UDisposition from Tender	−23.4K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	SVP, General Counsel and Sec.	DDisposition to Issuer	−6,700 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	SVP, General Counsel and Sec.	DDisposition to Issuer	−7,650 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	SVP, General Counsel and Sec.	DDisposition to Issuer	−8,500 sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	SVP, General Counsel and Sec.	DDisposition to Issuer	−24.3K sh	—	—	0
2021-11-19	ACCELERON PHARMA INCOption to Purchase Common StockD Disposition to Issuer	SVP, General Counsel and Sec.	DDisposition to Issuer	−18.8K sh	—	—	0
2021-11-09	ACCELERON PHARMA INCM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+4,500 sh	$29.37	+$132K	23,423
2021-11-09	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−4,500 sh	—	—	0
2021-09-21	ACCELERON PHARMA INCM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+5,200 sh	$30.17	+$157K	24,123
2021-09-21	ACCELERON PHARMA INCM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+1,450 sh	$41.20	+$59.7K	25,573
2021-09-21	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−6,650 sh	$150.05	−$998K	18,923
2021-09-21	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−5,200 sh	—	—	0
2021-09-21	ACCELERON PHARMA INCOption to Purchase Common StockM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	−1,450 sh	—	—	0
2021-09-09	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−1,407 sh	$130.00	−$183K	18,923
2021-09-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−6 sh	$130.00	−$780	20,330
2021-09-07	ACCELERON PHARMA INCF Tax Payment	SVP, General Counsel and Sec.	FTax Payment	−587 sh	$129.36	−$75.9K	20,336
2021-06-07	ACCELERON PHARMA INCF Tax Payment	SVP, General Counsel and Sec.	FTax Payment	−108 sh	$126.69	−$13.7K	20,923
2021-01-29	ACCELERON PHARMA INCA Award	SVP, General Counsel and Sec.	AAward	+4,868 sh	—	—	21,031
2021-01-29	ACCELERON PHARMA INCOption to Purchase Common StockA Award	SVP, General Counsel and Sec.	AAward	+18.8K sh	—	—	18,806
2021-01-05	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−1,900 sh	$122.46	−$233K	16,319
2021-01-05	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−56 sh	$122.93	−$6,884.08	16,263
2021-01-05	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−100 sh	$124.30	−$12.4K	16,163
2021-01-04	ACCELERON PHARMA INCF Tax Payment	SVP, General Counsel and Sec.	FTax Payment	−942 sh	$124.31	−$117K	18,219
2020-09-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−1,071 sh	$89.20	−$95.5K	20,090
2020-09-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−929 sh	$89.85	−$83.5K	19,161
2020-04-08	ACCELERON PHARMA INCM Exercise/Conversion	SVP, General Counsel and Sec.	MExercise/Conversion	+6,000 sh	$27.97	+$168K	27,161
2020-04-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−900 sh	$83.49	−$75.1K	26,261
2020-04-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−700 sh	$84.62	−$59.2K	25,561
2020-04-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−2,883 sh	$85.77	−$247K	22,678
2020-04-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−1,100 sh	$86.69	−$95.4K	21,578
2020-04-08	ACCELERON PHARMA INCS Sale	SVP, General Counsel and Sec.	SSale	−417 sh	$87.53	−$36.5K	21,161

Recent filings

Accepted (ET)
Aug 144
Veness Adam M0001778623-26-000009
SEC(opens sec.gov)
Aug 114
Veness Adam M0001778623-26-000007
SEC(opens sec.gov)
Jun 184
Veness Adam M0001778623-26-000005
SEC(opens sec.gov)
Feb 44
Veness Adam M0001778623-26-000002
SEC(opens sec.gov)
Feb 44
Veness Adam M0000950170-25-013488
SEC(opens sec.gov)
May 284
Veness Adam M0000950170-24-065566
SEC(opens sec.gov)
Jan 264
Veness Adam M0000950170-24-007994
SEC(opens sec.gov)
Feb 74
Veness Adam M0001209191-23-007500
SEC(opens sec.gov)
May 44
Veness Adam M0001209191-22-027079
SEC(opens sec.gov)
Nov 224
Veness Adam M0001104659-21-142271
SEC(opens sec.gov)

Companies

Address

C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR

NEW YORK, NY, 10036